Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Melanoma, a deadly skin cancer, has historically faced limited treatment options with poor outcomes for metastatic disease.
• Pre-2011 therapies like interleukin-2 and chemotherapy showed low efficacy and high toxicity.
• Early diagnosis is crucial for favorable prognosis, but advanced stages present significant challenges.

Purpose of the Study:

• To review the historical evolution of melanoma treatment strategies.
• To highlight the development and impact of targeted therapies and immunotherapies.
• To discuss future directions in overcoming therapeutic resistance in melanoma.

Main Methods:

• Review of scientific literature on melanoma treatment advancements.
• Analysis of drug discovery, synthesis, and mechanisms of action for key therapies.
• Examination of clinical outcomes comparing novel treatments with traditional agents.

Main Results:

• Targeted therapies (B-Raf and MEK inhibitors) benefit patients with B-Raf mutated melanoma.
• Immunotherapies (anti-CTLA-4 and anti-PD-1 antibodies) are effective for B-Raf wild-type melanoma.
• Both targeted therapies and immunotherapies have markedly improved survival in unresectable melanoma compared to alkylating agents.

Conclusions:

• Modern targeted therapies and immunotherapies represent a paradigm shift in melanoma treatment.
• These novel approaches have significantly enhanced patient survival rates.
• Future research must focus on understanding and overcoming resistance mechanisms to further improve long-term outcomes.